Patents by Inventor Bira Arya
Bira Arya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10765694Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: GrantFiled: July 7, 2016Date of Patent: September 8, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
-
Publication number: 20200022999Abstract: A fusion molecule is provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety. The targeting polypeptide and the nucleic acid binding moiety include specific the amino acid sequences. A fusion molecule is also provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety adapted to bind a double-stranded RNA or to a small hairpin RNA. The targeting polypeptide being IL6 or IL21 or a fragment thereof.Type: ApplicationFiled: October 7, 2019Publication date: January 23, 2020Inventors: Bira Arya, Michael R. Simon
-
Patent number: 10485879Abstract: A fusion molecule is provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety. The targeting polypeptide and the nucleic acid binding moiety include specific the amino acid sequences. A fusion molecule is also provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety adapted to bind a double-stranded RNA or to a small hairpin RNA. The targeting polypeptide being CCL27 or CCL11 or a fragment thereof.Type: GrantFiled: June 18, 2018Date of Patent: November 26, 2019Assignees: Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of HealthInventors: Bira Arya, Michael R. Simon
-
Publication number: 20180280526Abstract: A fusion molecule is provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety. The targeting polypeptide and the nucleic acid binding moiety include specific the amino acid sequences. A fusion molecule is also provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety adapted to bind a double-stranded RNA or to a small hairpin RNA. The targeting polypeptide being CCL27 or CCL11 or a fragment thereof.Type: ApplicationFiled: June 18, 2018Publication date: October 4, 2018Inventors: Bira Arya, Michael R. Simon
-
Patent number: 10077296Abstract: The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3?/CCL20 or ?-defensin mDF2?. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.Type: GrantFiled: August 16, 2012Date of Patent: September 18, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Bira Arya, Dan Longo, Igor Espinoza-Delgardo
-
Patent number: 9937248Abstract: Disclosed herein are DNA-based vaccines against amyloid ? peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid ? peptides, such as amino acids 1-11 of A?, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant.Type: GrantFiled: September 2, 2016Date of Patent: April 10, 2018Assignee: Cyvax, Inc.Inventor: Bira Arya
-
Patent number: 9657269Abstract: Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25+) a pan B cell marker such as B220 (B220+), and also express CD19 (CD19+). These regulatory B cells suppress resting and activated T cells in cell contact-dependent manner. Methods for generating these regulatory B cells are also disclosed herein, as are methods for using these regulatory B cells to produce regulatory T cells (Treg). In some embodiments, methods for treating an immune-mediated disorder, such as an autoimmune disease, transplant rejection, graft-versus-host disease or inflammation, are disclosed. These methods include increasing regulatory B cell number or activity and/or by administering autologous regulatory B cells. Methods for treating cancer are also disclosed herein. These methods include decreasing regulatory B cell activity and/or number.Type: GrantFiled: November 25, 2015Date of Patent: May 23, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bira Arya, Purevdorj B. Olkhanud, Monica Bodogai
-
Publication number: 20170042990Abstract: Disclosed herein are DNA-based vaccines against amyloid ? peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid ? peptides, such as amino acids 1-11 of A?, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant.Type: ApplicationFiled: September 2, 2016Publication date: February 16, 2017Inventors: Bira Arya, Richard Markham
-
Publication number: 20160310609Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: ApplicationFiled: July 7, 2016Publication date: October 27, 2016Inventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
-
Patent number: 9433665Abstract: Disclosed herein are DNA-based vaccines against amyloid ? peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid ? peptides, such as amino acids 1-11 of A?, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant.Type: GrantFiled: January 10, 2014Date of Patent: September 6, 2016Assignee: Cyvax, Inc.Inventors: Bira Arya, Richard Markham
-
Patent number: 9415116Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: GrantFiled: March 20, 2014Date of Patent: August 16, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
-
Publication number: 20160152951Abstract: Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25+) a pan B cell marker such as B220 (B220+), and also express CD19 (CD19+). These regulatory B cells suppress resting and activated T cells in cell contact-dependent manner. Methods for generating these regulatory B cells are also disclosed herein, as are methods for using these regulatory B cells to produce regulatory T cells (Treg). In some embodiments, methods for treating an immune-mediated disorder, such as an autoimmune disease, transplant rejection, graft-versus-host disease or inflammation, are disclosed. These methods include increasing regulatory B cell number or activity and/or by administering autologous regulatory B cells. Methods for treating cancer are also disclosed herein. These methods include decreasing regulatory B cell activity and/or number.Type: ApplicationFiled: November 25, 2015Publication date: June 2, 2016Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServInventors: Bira Arya, Purevdorj B. Olkhanud, Monica Bodogai
-
Patent number: 9238684Abstract: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.Type: GrantFiled: January 14, 2014Date of Patent: January 19, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bira Arya, Vladimir L. Larionov
-
Patent number: 9228171Abstract: Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25+) a pan B cell marker such as B220 (B220+), and also express CD19 (CD19+). These regulatory B cells suppress resting and activated T cells in cell contact-dependent manner. Methods for generating these regulatory B cells are also disclosed herein, as are methods for using these regulatory B cells to produce regulatory T cells (Treg). In some embodiments, methods for treating an immune-mediated disorder, such as an autoimmune disease, transplant rejection, graft-versus-host disease or inflammation, are disclosed. These methods include increasing regulatory B cell number or activity and/or by administering autologous regulatory B cells. Methods for treating cancer are also disclosed herein. These methods include decreasing regulatory B cell activity and/or number.Type: GrantFiled: February 4, 2011Date of Patent: January 5, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bira Arya, Purevdorj B. Olkhanud, Monica Bodogai
-
Publication number: 20140377179Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: ApplicationFiled: March 20, 2014Publication date: December 25, 2014Applicant: The United States of America,as represented by the Secretary, Department of Health & Human ServicesInventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
-
Publication number: 20140234362Abstract: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.Type: ApplicationFiled: May 2, 2014Publication date: August 21, 2014Applicant: The U.S.A, as represented by the Secretary , Department of Health and Human ServicesInventors: Larry W. Kwak, Bira Arya
-
Publication number: 20140199338Abstract: Disclosed herein are DNA-based vaccines against amyloid ? peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid ? peptides, such as amino acids 1-11 of A?, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant.Type: ApplicationFiled: January 10, 2014Publication date: July 17, 2014Applicant: Cyvax, Inc.Inventors: Bira Arya, Richard Markham
-
Patent number: 8754030Abstract: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.Type: GrantFiled: September 9, 2013Date of Patent: June 17, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Larry W. Kwak, Bira Arya
-
Publication number: 20140127246Abstract: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Bira Arya, Vladimir L. Larionov
-
Patent number: 8703921Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: GrantFiled: April 15, 2009Date of Patent: April 22, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza